Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulate islet function after carbohydrate ingestion. Whether incretin hormones are of importance for islet function after ingestion of noncarbohydrate macronutrients is not known. This study therefore examined integrated incretin and islet hormone responses to ingestion of pure fat (oleic acid; 0.88 g/kg) or protein (milk and egg protein; 2 g/kg) over 5 h in healthy men, aged 20-25 yr (n=12); plain water ingestion served as control. Both intact (active) and total GLP-1 and GIP levels were determined as was plasma activity of dipeptidyl peptidase-4 (DPP-4). Following water ingestion, glucose, insulin, glucagon, GLP-1, and GIP levels and DPP-4 activity were stable during the 5-h study period. Both fat and protein ingestion increased insulin, glucagon, GIP, and GLP-1 levels without affecting glucose levels or DPP-4 activity. The GLP-1 responses were similar after protein and fat, whereas the early (30 min) GIP response was higher after protein than after fat ingestion (P<0.001). This was associated with sevenfold higher insulin and glucagon responses compared with fat ingestion (both P<0.001). After protein, the early GIP, but not GLP-1, responses correlated to insulin (r(2)=0.86; P=0.0001) but not glucagon responses. In contrast, after fat ingestion, GLP-1 and GIP did not correlate to islet hormones. We conclude that, whereas protein and fat release both incretin and islet hormones, the early GIP secretion after protein ingestion may be of primary importance to islet hormone secretion.

[1]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[2]  J. Holst,et al.  Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT , 2007, Journal of clinical pharmacology.

[3]  J. Holst,et al.  Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. , 2007, The American journal of clinical nutrition.

[4]  C. Deacon,et al.  Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. , 2006, Endocrinology.

[5]  M. Prentki,et al.  Fatty acid signaling in the beta-cell and insulin secretion. , 2006, Diabetes.

[6]  J. Holst Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005 , 2006, Diabetologia.

[7]  J. Foley,et al.  Alpha cell function in health and disease: influence of glucagon-like peptide-1 , 2005, Diabetologia.

[8]  C. Deacon,et al.  What do we know about the secretion and degradation of incretin hormones? , 2005, Regulatory Peptides.

[9]  P. Brubaker,et al.  Nutrient, neural and endocrine control of glucagon-like peptide secretion. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[10]  J. Holst,et al.  Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? , 2004, Expert opinion on investigational drugs.

[11]  M. Camilleri,et al.  The gastrointestinal tract and glucose tolerance , 2004, Current opinion in clinical nutrition and metabolic care.

[12]  B. Ahrén Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  K. Frayn,et al.  Vagal stimulation exaggerates the inhibitory ghrelin response to oral fat in humans. , 2004, The Journal of endocrinology.

[14]  W. Creutzfeldt,et al.  New developments in the incretin concept , 1985, Diabetologia.

[15]  J. Holst,et al.  GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.

[16]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[17]  E. Husebye,et al.  Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics , 2001, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[18]  K. Frayn,et al.  Carbohydrate and fat have different effects on plasma leptin concentrations and adipose tissue leptin production. , 2001, Clinical science.

[19]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[20]  T. Dakka,et al.  Peptide YY, Glucagon-Like Peptide-1, and Neurotensin Responses to Luminal Factors in the Isolated Vascularly Perfused Rat Ileum. , 1998, Endocrinology.

[21]  B. Ahrén Glucagon‐like peptide‐1 (GLP‐1): A gut hormone of potential interest in the treatment of diabetes , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  T. Dakka,et al.  Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. , 1998, Endocrinology.

[23]  A. Niijima,et al.  Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. , 1996, The American journal of physiology.

[24]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[25]  J. Holst,et al.  Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. , 1995, The American journal of physiology.

[26]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[27]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[28]  V. Marks,et al.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.

[29]  D. Kelley,et al.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.

[30]  H. Mekhjian,et al.  Localization of gastric inhibitory polypeptide release by intestinal glucose perfusion in man. , 1977, Gastroenterology.

[31]  H. Mekhjian,et al.  Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. , 1976, Gastroenterology.

[32]  I. Cleator,et al.  Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. , 1975, American journal of surgery.

[33]  J. Brown,et al.  Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. , 1974, The Journal of clinical endocrinology and metabolism.